The 3 most recent market catalysts affecting $TNYA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 85
Tenaya Therapeutics shares are trading higher after the company announced the FDA has granted RMAT designation to TN-401, gene therapy candidate for the treatment of PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
The FDA's RMAT (Regenerative Medicine Advanced Therapy) designation is a significant positive catalyst for Tenaya Therapeutics. This designation is granted to promising regenerativ…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 85
FDA Grants Regenerative Medicine Advanced Therapy Designation To Tenaya Therapeutics’ TN-401, Gene Therapy Candidate For Treatment Of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Tenaya Therapeutics announced that its gene therapy candidate, TN-401, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA. This designation is a …
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 95
Tenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M Estimate
Tenaya Therapeutics announced Q2 earnings per share of $(0.20), missing the analyst consensus of $(0.05) by a substantial 300%. Additionally, quarterly sales of $1.110 million fell…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.